Semaglutide in Obesity: Unmet Needs in Men.
作者信息
Jensterle Mojca, Rizzo Manfredi, Janež Andrej
机构信息
Department of Endocrinology, Diabetes and Metabolic Disease, University Medical Centre Ljubljana, Zaloska 7, 1000, Ljubljana, Slovenia.
Faculty of Medicine, University of Ljubljana, Vrazov trg 2, 1000, Ljubljana, Slovenia.
出版信息
Diabetes Ther. 2023 Mar;14(3):461-465. doi: 10.1007/s13300-022-01360-7. Epub 2023 Jan 7.
Abstract
摘要
相似文献
1
Semaglutide in Obesity: Unmet Needs in Men.司美格鲁肽治疗肥胖症：男性未满足的需求
Diabetes Ther. 2023 Mar;14(3):461-465. doi: 10.1007/s13300-022-01360-7. Epub 2023 Jan 7.
2
Clinical review of subcutaneous semaglutide for obesity.皮下司美格鲁肽治疗肥胖的临床综述。
J Clin Pharm Ther. 2022 Feb;47(2):184-193. doi: 10.1111/jcpt.13574. Epub 2021 Dec 28.
3
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.持续每周皮下注射司美格鲁肽与安慰剂对超重或肥胖成年人体重维持的影响：STEP 4 随机临床试验。
JAMA. 2021 Apr 13;325(14):1414-1425. doi: 10.1001/jama.2021.3224.
4
Clinical Impact of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist, on Obesity Management: A Review.胰高血糖素样肽-1受体激动剂司美格鲁肽对肥胖管理的临床影响：一项综述
Clin Pharmacol. 2022 Aug 3;14:61-67. doi: 10.2147/CPAA.S374741. eCollection 2022.
5
Pharmacological profile of once-weekly injectable semaglutide for chronic weight management.每周一次注射用司美格鲁肽的慢性体重管理药理学特征。
Expert Rev Clin Pharmacol. 2022 Mar;15(3):251-267. doi: 10.1080/17512433.2022.2070473. Epub 2022 Apr 27.
6
Effectiveness in Real World of Once Weekly Semaglutide in People with Type 2 Diabetes: Glucagon-Like Peptide Receptor Agonist Naïve or Switchers from Other Glucagon-Like Peptide Receptor Agonists: Results from a Retrospective Observational Study in Umbria.司美格鲁肽每周一次用于2型糖尿病患者的真实世界有效性：初治或从其他胰高血糖素样肽受体激动剂转换而来的患者：一项在翁布里亚进行的回顾性观察研究结果
Diabetes Ther. 2022 Mar;13(3):551-567. doi: 10.1007/s13300-022-01218-y. Epub 2022 Mar 1.
7
Cardiometabolic risk factors efficacy of semaglutide in the STEP program.司美格鲁肽在STEP项目中的心血管代谢危险因素疗效。
Postgrad Med. 2022 Jan;134(sup1):18-27. doi: 10.1080/00325481.2022.2147325.
8
The role of oral semaglutide in managing type 2 diabetes in Indian clinical settings: Addressing the unmet needs.口服司美格鲁肽在印度临床环境中管理 2 型糖尿病的作用：满足未满足的需求。
Diabetes Metab Syndr. 2022 Jun;16(6):102508. doi: 10.1016/j.dsx.2022.102508. Epub 2022 May 23.
9
The Effectiveness of GLP-1 Receptor Agonist Semaglutide on Body Composition in Elderly Obese Diabetic Patients: A Pilot Study.胰高血糖素样肽-1受体激动剂司美格鲁肽对老年肥胖糖尿病患者身体成分的影响：一项初步研究。
Medicines (Basel). 2022 Sep 16;9(9):47. doi: 10.3390/medicines9090047.
10
Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?司美格鲁肽用于2型糖尿病——它是最佳的胰高血糖素样肽1受体激动剂（GLP-1R激动剂）吗？
Expert Opin Drug Metab Toxicol. 2018 Mar;14(3):371-377. doi: 10.1080/17425255.2018.1441286. Epub 2018 Feb 23.
引用本文的文献
1
Real-World Sex Differences in Response to Treatment with Glucagon-like Peptide-1 Receptor Agonists: Analysis of Single-Center Outpatient Case Series.胰高血糖素样肽-1受体激动剂治疗反应的真实世界性别差异：单中心门诊病例系列分析
Medicina (Kaunas). 2025 Jul 25;61(8):1343. doi: 10.3390/medicina61081343.
2
Weight reduction over time in tirzepatide-treated participants by early weight loss response: Post hoc analysis in SURMOUNT-1.根据早期体重减轻反应，替尔泊肽治疗参与者随时间的体重减轻情况：SURMOUNT-1事后分析
Diabetes Obes Metab. 2025 Sep;27(9):5064-5071. doi: 10.1111/dom.16554. Epub 2025 Jul 17.
3
Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity.胰淀素：从作用机制到在糖尿病和肥胖症中的未来临床潜力
Diabetes Ther. 2025 Jun;16(6):1207-1227. doi: 10.1007/s13300-025-01733-8. Epub 2025 May 7.
4
MASLD: Prevalence, Mechanisms, and Sex-Based Therapies in Postmenopausal Women.绝经后女性的代谢功能障碍相关脂肪性肝病：患病率、发病机制及基于性别的治疗方法
Biomedicines. 2025 Apr 2;13(4):855. doi: 10.3390/biomedicines13040855.
5
Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment.司美格鲁肽作为一种胰高血糖素样肽-1（GLP-1）激动剂：肥胖治疗的一项突破。
Pharmaceuticals (Basel). 2025 Mar 12;18(3):399. doi: 10.3390/ph18030399.
6
Sex Differences in the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Weight Reduction: A Systematic Review and Meta-Analysis.胰高血糖素样肽-1受体激动剂减肥效果的性别差异：一项系统评价与荟萃分析
J Diabetes. 2025 Mar;17(3):e70063. doi: 10.1111/1753-0407.70063.
7
Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonist.在司伏度肽（一种胰高血糖素/GLP-1受体双重激动剂）的2期试验中，对BMI≥27kg/m²的人群按性别和基线BMI进行亚组分析。
Diabetes Obes Metab. 2025 Apr;27(4):1773-1782. doi: 10.1111/dom.16167. Epub 2025 Jan 16.
8
Insights into the neurobiology of weight loss after bariatric surgery and GLP-1R agonists.对减肥手术后体重减轻及胰高血糖素样肽-1受体激动剂的神经生物学见解。
Neuropharmacology. 2025 Mar 1;265:110269. doi: 10.1016/j.neuropharm.2024.110269. Epub 2024 Dec 14.
9
Representation of racialised and ethnically diverse populations in multicentre randomised controlled trials of GLP-1 medicines for obesity: a systematic review and meta-analysis of gaps.种族化和族裔多样化人群在 GLP-1 类药物治疗肥胖的多中心随机对照试验中的代表性：差距的系统评价和荟萃分析。
BMJ Glob Health. 2024 Nov 28;9(11):e017177. doi: 10.1136/bmjgh-2024-017177.
10
One-Year Weight Reduction With Semaglutide or Liraglutide in Clinical Practice.临床实践中司美格鲁肽或利拉鲁肽的一年减重效果。
JAMA Netw Open. 2024 Sep 3;7(9):e2433326. doi: 10.1001/jamanetworkopen.2024.33326.
本文引用的文献
1
Once-Weekly Semaglutide in Adolescents with Obesity.每周一次司美格鲁肽治疗肥胖青少年。
N Engl J Med. 2022 Dec 15;387(24):2245-2257. doi: 10.1056/NEJMoa2208601. Epub 2022 Nov 2.
2
Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert group.将胰高血糖素样肽-1 受体激动剂的心血管结局试验结果转化为临床实践：来自东欧和南欧糖尿病专家组的建议。
Int J Cardiol. 2022 Oct 15;365:8-18. doi: 10.1016/j.ijcard.2022.07.017. Epub 2022 Jul 26.
3
Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review.GLP-1 RA 在有或无糖尿病患者的体重管理中的疗效：一篇叙述性综述。
Adv Ther. 2022 Jun;39(6):2452-2467. doi: 10.1007/s12325-022-02153-x. Epub 2022 May 3.
4
Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care.胰高血糖素样肽-1受体激动剂治疗反应中的性别差异：糖尿病和肥胖症个性化护理的机遇
J Pers Med. 2022 Mar 13;12(3):454. doi: 10.3390/jpm12030454.
5
Patient initiation and maintenance of GLP-1 RAs for treatment of obesity.患者起始和维持 GLP-1RA 治疗肥胖症。
Expert Rev Clin Pharmacol. 2021 Oct;14(10):1193-1204. doi: 10.1080/17512433.2021.1947796. Epub 2021 Jul 7.
6
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.持续每周皮下注射司美格鲁肽与安慰剂对超重或肥胖成年人体重维持的影响：STEP 4 随机临床试验。
JAMA. 2021 Apr 13;325(14):1414-1425. doi: 10.1001/jama.2021.3224.
7
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.司美格鲁肽 2·4 毫克每周一次治疗超重或肥胖、以及 2 型糖尿病成人患者（STEP 2）：一项随机、双盲、双模拟、安慰剂对照、3 期临床试验。
Lancet. 2021 Mar 13;397(10278):971-984. doi: 10.1016/S0140-6736(21)00213-0. Epub 2021 Mar 2.
8
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.皮下司美格鲁肽与安慰剂作为强化行为疗法辅助手段对超重或肥胖成人体重的影响：STEP 3 随机临床试验。
JAMA. 2021 Apr 13;325(14):1403-1413. doi: 10.1001/jama.2021.1831.
9
Once-Weekly Semaglutide in Adults with Overweight or Obesity.每周一次司美格鲁肽在超重或肥胖成人中的应用。
N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10.
10
Male Obesity Associated Gonadal Dysfunction and the Role of Bariatric Surgery.男性肥胖相关性腺功能障碍与减重手术的作用。
Front Endocrinol (Lausanne). 2020 Jun 19;11:408. doi: 10.3389/fendo.2020.00408. eCollection 2020.
Zotero 插件